• 05/27/2026, Sophia Antipolis, France

    Launch of a capital increase

    Median Technologies Launches a Capital Increase of €40 million, with Potential Upsize to €50 million, to Support the Deployment of eyonis® LCS in the U.S. and Europe and Advance New Clinical Indications for Its Proprietary eyonis® Pan-Cancer Early Diagnostics Suite. Access the documentation here Disclaimer: This communication and the information and documents relating to it may […]
    Read more
  • 05/26/2026, Sophia Antipolis, France

    Median Technologies to showcase iCRO’s central and AI-powered imaging services for oncology clinical trials at ASCO 2026

    The Company will be participating in the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from May 29 to June 2, McCormick Place, Chicago, IL, USA.
    Read more Download 20260526_PR_ASCO2026_EN.pdf
  • 05/21/2026, Sophia Antipolis, France

    Median Technologies announces the availability of the preparatory documents for the Annual Shareholders’ Ordinary and Extraordinary General Meeting on June 10, 2026

    Press release – For immediate release – 5:45 pm CEST Median Technologies announces the availability of the preparatory documents for the Annual Shareholders’ Ordinary and Extraordinary General Meeting on June 10, 2026 The shareholders of Median Technologies (FR0011049824, ALMDT, “Median” or “The Company”) are invited to participate in the Annual Shareholders’ Ordinary and Extraordinary General […]
    Read more Download 20260521_PR_OEGM_10June2026_EN_Final.pdf
  • 05/04/2026, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of April 30, 2026

    Disclosure of total number of voting rights and number of shares in the capital as of April 30, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20260504_PR_shares_votingrights_April2026.pdf
  • 04/23/2026, Sophia Antipolis, France

    Median Technologies reports full-year 2025 financial results and provides key Q1 2026 business highlights

    Median Technologies today reported its 2025 consolidated annual financial results, and provided key business highlights for the first quarter of 2026. The consolidated financial statements for the financial year ended December 31, 2025, were audited and approved by the Company’s Board of Directors on April 22, 2026.
    Read more Download 20260423_PR_FY2025_Q12026_EN-1.pdf
  • 04/07/2026, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of March 31, 2026

    Disclosure of total number of voting rights and number of shares in the capital as of March 31, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20260407_PR_shares_votingrights_March2026.pdf
  • 03/18/2026, Sophia Antipolis, France

    Median Technologies achieves ISO 13485:2016 certification for eyonis® Medical Device Quality Management System

    Press release – For immediate release – 5:45 pm CET Median Technologies achieves ISO 13485:2016 certification for eyonis® Medical Device Quality Management System Certification of a robust and compliant Quality Management System for AI-based Software as Medical Devices, as per internationally recognized medical device regulatory standards Pledge of quality to support the industrialization, scaling, and deployment […]
    Read more Download 20260318_PR_ISO15485_EN_final.pdf
  • 03/13/2026, Sophia Antipolis, France

    Median Technologies meets the eligibility conditions for the PEA-PME scheme

    Press release – For immediate release – 5:45 pm CET Median Technologies meets the eligibility conditions for the PEA-PME scheme Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading […]
    Read more Download 20260313_PR_PEAPME_EN.pdf
  • 03/09/2026, Sophia Antipôlis, France

    Disclosure of total number of voting rights and number of shares in the capital as of February 28, 2026

    Disclosure of total number of voting rights and number of shares in the capital as of February 28, 2026, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20260309_PR_shares_votingrights_Feb2026.pdf
  • 03/02/2026, Sophia Antipolis, France

    Median Technologies to showcase eyonis® LCS, its AI/ML-based Software as a Medical Device for lung cancer screening, at the European Congress of Radiology

    The Median eyonis® team will welcome attendees at Booth #AI-16, AI Exhibition, Expo X1, from March 4 to March 7, to present the latest developments related to eyonis® Lung Cancer Screening (LCS), its AI-powered Software as a Medical Device (SaMD).
    Read more Download 20260302_PR_ECR2026_EN_final.pdf
    • 1 … 45